DOCSLIB.ORG

University of Groningen Stereoselectivity in the Hepatic Metabolism and Transport of Quaternary Drugs of the Morphinan Type Lant

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
University of Groningen Stereoselectivity in the Hepatic Metabolism and Transport of Quaternary Drugs of the Morphinan Type Lant University of Groningen Stereoselectivity in the hepatic metabolism and transport of quaternary drugs of the morphinan type Lanting, Aleida Bartha Louisa IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2000 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Lanting, A. B. L. (2000). Stereoselectivity in the hepatic metabolism and transport of quaternary drugs of the morphinan type. s.n. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 24-09-2021 In this thesisthe potential of some quaternaryamine derivativesof the morphinan analoguesdextrorphan, levorphanol, dextromethorphan and levomethorphanas model compoundswas investigatedto study stereoselectivityin hepatic metabolismand transport of cationic drugs.These model compoundspossess a rigid stereochemicalstructure, resulting in major differencesin receptor affinity. We assumedthat the major influenceof the stereochemicalstructure on the receptor level might also causedifferences in carrier-mediatedtransport and biotransformation processes. During the developmentof a reversed-phaseHPLC separationsystem for the analysisof the purity of the quaternizedmorphinans (N-methyl dextrorphan, N-methyl levorphanol,N-methyl dextromethorphanand N-methyl levomethorphan)it became clear that silanophilicinteractions rvith the stationaryphase were involved.Some complicatingfactors were observed:The separationwas sensitiveto the brand and type of column material,to slightpH changesof the mobile phaseand to column overloading.However, these silanophilic interactions also played a decisiverole in the selectivityof the stationaryphase, and therefore no attempts were made to suppress the latter. SpherisorbODS-I stationaryphases appeared to be adequate in the separationof the four morphinansand were chosenfor the estimation of the purity of synthesizedquaternary ammonium morphinans (Chapter 5.1). For the analysisof biologicalsamples, a C6-bondedstationary phase and a gradient of acetonitrile in 0.02 M sodium phosphatebuffer with a low pH as a mobile phase was used.This method was able to separatethe respectiveparent compounds, their primary metabolitesand some conjugatesin a single run. The silanophilic interactionsalso causedsome troublesomeeff'ects in the bioanalysisof the metabolites of the quaternarymorphinans. First, the separationrvas affected b)'column degradationand by batch-to-batchdiff'erences in column material.Small adaptations of the mobile phasecomposition were made to compensatefor small changesin chromatographicperformance. Another effect of the involvementof silanophilic interactionswas that proteins in the biological sampleshad a detrimental effect on the columnperformance. A precolumnswitching technique on a reversedphase C8 column with a backflushstep to introduce the analyteson the HPLC column was successfullyused (Chanter5.2). To study the hepatic transport and metabolism,isolated Wistar rat liver perfusionswere performed. Experimentswith radioactivelylabelled N-methyl dextrorphan,N-methyl levorphanol,N-methyl dextromethorphan,and N-methyl levomethorphanshowed that the initial uptake of the former pair of enantiomerswas not stereoselective,but N-methyl dextromethorphanwas taken up slightlyfaster in the liver than N-methyllevomethorphan (Chapter 5.5, and Chapter5.6 resp.).Further transport stepscould not be observedbecause the compoundswere extensively metabolizedin a stereoselectiveway. Samplestaken during the liver perfusionswere analyzedwith the HPLC method describedabove. Very distinct radiochromatograms were obtained for the enantiomericpairs. Experimentswith selectiveenzl,matic LJ I hydrolysisshowed that glucuronidesand sulfatesof the morphinans were present in the samples.Further identification of the metaboliteswas accompishedby ionspray LCIMS. Liver perfusionswith stable isotope labelled compound were performed and the sampleswere analyzedwith a gradient HPLC method with the same stationary phase but with a volatile mobile phase.Both N-methyl dextrorphan and N-methyl levorphanol were found glucuronidatedand conjugatedwith glutathione.In addition, N-methyl levorphanol was hydroxylatedand subsequentlyglucuronidated, and a sulfoconjugateof N-methyl levorphanol was also found (Chapter 5.3). When sfudying the metabolism of N-methyl dextromethorphanand N-methyl levomethorphan,the O-demethylationsof both substancestook place at about the same velocity.Further metabolism stepswere glucuronidationand glutathioneconjugation for the O-demethylatedN-methyl dextromethorphanand glucuronidation,glutathione conjugation,sulfoconjugation and hydroxylationfor the O-demethylatedN-methyt levomethorphan(Chapter 5.4). The O-demethylationof N-methyl dextromethorphanand N-methyl levomethorphanmay be under control of a cytochromeP450 isozymethat is also responsiblefor the genetic polymorphismof the debrisoquinetype. In that case,the O-demethylationof the two enantiomersshould be reduced in the livers of Dark Agouti rats, which is an animal model for this geneticpolymorphism. We performed isolatedrat liver perfusionswith livers of these Dark Agouti rats to test this assumption.The O-demethl,lationof N-methyl dextromethorphanindeed was largely reduced.The O-demethylationof N-methyllevomethorphan, however, was Iargely unaffected.The velocity of the enzymaticreaction was almost identical to that in Wistar rats. Probably, other isoformsof cytochromeP450 played a role in the O-demethylationof N-methyl levomethorphan.Unfortunately, the Dark Agouti rat did not appear to be a satisfyinganimal model to study stereoselectivityin other transport phenomenathan the initial uptake into the liver of cationic drugs (Chapter 5.7). Finally, concentratingon the initial uptake of the cationic model compounds, inhibitionexperiments with procainamideethobromide and digoxinin isolatedrat liver perfusionswere performed to characterizethe type of carrier systemthat was involved in the uptake of N-methyl dextrorphan and N-methyl levorphanol.It appeared that the uptake in the liver of the enantiomersN-methyl dextrorphan and N-methyl levorphanol occurred partly via the type I transport systemand partly via the type II or multispecifictransport system.The uptake via the type II transport systemwas found to be stereoselective:The half-life of N-methyl levorphanolappeared to be about 50 % larger than that of its enantiomerN-methyl dextrorphan (Chapter 5.8). It is concludedthat the quaternaryammonium derivativesof morphinan enantiomersstudied provide interestingmodel compoundsfor the study of carrier-mediatedtransport processesfor cationic drugs.Their disadvantagefor studies with intact organs however is that extensivemetabolism occcurs at the same time and this largely complicatesthe study of concomittanttransport steps.Therefore, future srudiesshould be performed in isolatedplasma membrane vesiclesor in reconstituted membrane systemsincluding the transport proteins. Recent studiesin our laboratories using expressionsystems of these proteins, cloned by us and others, indeed demonstratestereoselectivity in membrane transport of cationic drugs..
Load more

Recommended publications
  • DEMAND REDUCTION a Glossary of Terms
    UNITED NATIONS PUBLICATION Sales No. E.00.XI.9 ISBN: 92-1-148129-5 ACKNOWLEDGEMENTS This document was prepared by the: United Nations International Drug Control Programme (UNDCP), Vienna, Austria, in consultation with the Commonwealth of Health and Aged Care, Australia, and the informal international reference group. ii Contents Page Foreword . xi Demand reduction: A glossary of terms . 1 Abstinence . 1 Abuse . 1 Abuse liability . 2 Action research . 2 Addiction, addict . 2 Administration (method of) . 3 Adverse drug reaction . 4 Advice services . 4 Advocacy . 4 Agonist . 4 AIDS . 5 Al-Anon . 5 Alcohol . 5 Alcoholics Anonymous (AA) . 6 Alternatives to drug use . 6 Amfetamine . 6 Amotivational syndrome . 6 Amphetamine . 6 Amyl nitrate . 8 Analgesic . 8 iii Page Antagonist . 8 Anti-anxiety drug . 8 Antidepressant . 8 Backloading . 9 Bad trip . 9 Barbiturate . 9 Benzodiazepine . 10 Blood-borne virus . 10 Brief intervention . 11 Buprenorphine . 11 Caffeine . 12 Cannabis . 12 Chasing . 13 Cocaine . 13 Coca leaves . 14 Coca paste . 14 Cold turkey . 14 Community empowerment . 15 Co-morbidity . 15 Comprehensive Multidisciplinary Outline of Future Activities in Drug Abuse Control (CMO) . 15 Controlled substance . 15 Counselling and psychotherapy . 16 Court diversion . 16 Crash . 16 Cross-dependence . 17 Cross-tolerance . 17 Custody diversion . 17 Dance drug . 18 Decriminalization or depenalization . 18 Demand . 18 iv Page Demand reduction . 19 Dependence, dependence syndrome . 19 Dependence liability . 20 Depressant . 20 Designer drug . 20 Detoxification . 20 Diacetylmorphine/Diamorphine . 21 Diuretic . 21 Drug . 21 Drug abuse . 22 Drug abuse-related harm . 22 Drug abuse-related problem . 22 Drug policy . 23 Drug seeking . 23 Drug substitution . 23 Drug testing . 24 Drug use .
    [Show full text]
  • Drugs of Abuseon September Archived 13-10048 No
    U.S. DEPARTMENT OF JUSTICE DRUG ENFORCEMENT ADMINISTRATION WWW.DEA.GOV 9, 2014 on September archived 13-10048 No. v. Stewart, in U.S. cited Drugs of2011 Abuse EDITION A DEA RESOURCE GUIDE V. Narcotics WHAT ARE NARCOTICS? Also known as “opioids,” the term "narcotic" comes from the Greek word for “stupor” and originally referred to a variety of substances that dulled the senses and relieved pain. Though some people still refer to all drugs as “narcot- ics,” today “narcotic” refers to opium, opium derivatives, and their semi-synthetic substitutes. A more current term for these drugs, with less uncertainty regarding its meaning, is “opioid.” Examples include the illicit drug heroin and pharmaceutical drugs like OxyContin®, Vicodin®, codeine, morphine, methadone and fentanyl. WHAT IS THEIR ORIGIN? The poppy papaver somniferum is the source for all natural opioids, whereas synthetic opioids are made entirely in a lab and include meperidine, fentanyl, and methadone. Semi-synthetic opioids are synthesized from naturally occurring opium products, such as morphine and codeine, and include heroin, oxycodone, hydrocodone, and hydromorphone. Teens can obtain narcotics from friends, family members, medicine cabinets, pharmacies, nursing 2014 homes, hospitals, hospices, doctors, and the Internet. 9, on September archived 13-10048 No. v. Stewart, in U.S. cited What are common street names? Street names for various narcotics/opioids include: ➔ Hillbilly Heroin, Lean or Purple Drank, OC, Ox, Oxy, Oxycotton, Sippin Syrup What are their forms? Narcotics/opioids come in various forms including: ➔ T ablets, capsules, skin patches, powder, chunks in varying colors (from white to shades of brown and black), liquid form for oral use and injection, syrups, suppositories, lollipops How are they abused? ➔ Narcotics/opioids can be swallowed, smoked, sniffed, or injected.
    [Show full text]
  • Proposal for Reclassification of Cough Medicines Containing Dextromethorphan, Opium Tincture, Squill Oxymel and Pholcodine to Restricted Medicines
    Proposal for reclassification of cough medicines containing dextromethorphan, opium tincture, squill oxymel and pholcodine to restricted medicines Purpose Medsafe has recently been alerted to instances of abuse of cough medicines containing dextromethorphan. Concern was raised over the easy availability of opioid (and opioid-like) cough medicines which can be bought at a pharmacy or supermarket without healthcare professional supervision. Dextromethorphan is a substance that does not belong to the opioid family but has a chemical structure closely resembling the opioids. Dextromethorphan has a history of abuse in New Zealand and other countries. There are also other cough medicines available as pharmacy medicines which have been noted as at least having a potential for abuse, for example cough medicines containing pholcodine and Gees linctus which contains anhydrous morphine. Pholcodine and anhydrous morphine are both opioids. Medsafe therefore requests that Medicines Classification Committee (MCC) considers reclassification of dextromethorphan, opium tincture, squill oxymel and pholcodine containing products to Pharmacist-Only (restricted) medicines. Medsafe considers that a reclassification to restricted medicine balances a need for better supervision whilst maintaining access for those who benefit from using these medicines. Background Dextromethorphan and misuse (1) Dextromethorphan (DXM) is the D- isomer of the codeine synthetic analogue, levorphanol. DXM also structurally resembles ketamine and phenycycline which are dissociative agents, meaning that they can be used to incite a type of general anesthesia characterized by analgesia and amnesia with minimal effect on respiratory function. DXM is an opioid, but because of its stereochemistry, DXM and its metabolites do not bind to the mu and delta opioid receptors, thus avoiding classic opioid toxicity.
    [Show full text]
  • Urine Drug Toxicology and Pain Management Testing
    Urine Drug Toxicology and Pain Management Testing Kara Lynch, PhD, DABCC University of California San Francisco San Francisco, CA Learning Objectives • Describe what chronic pain is, who is affected and how they are commonly treated • Explain the common methodologies used in pain management testing • Interpret urine drug testing results • Create protocols to minimize the occurrence of false positive or false negative results Pain – definition and types • Pain - an unpleasant sensory and emotional experience associated with actual or potential tissue damage • Chronic pain - pain that extends beyond the expected period of healing • Nociceptive Pain – Pain caused by tissue injury – Stimulus-evoked, high intensity – Opioid sensitive • Neuropathic Pain – Caused by nerve injury – Spontaneous activity – Develops in days or month – Opioid insensitive Chronic Pain Patients • Arthritis • Fibromyalgia – Osteoarthritis • Headaches – Rheumatoid arthritis – Migraine – Gout – Tension • Cancer – Cluster • Chronic non-cancer pain • Myofascial pain • Central pain syndrome • Neuropathic pain – CNS damage – Diabetic Peripheral – Multiple Sclerosis Neuropathy – Parkinson’s disease – Postherpetic neuralgia • Chronic abnominal pain • Neck and Back Pain – Intestinal obstructions Chronic Pain Medications • Opiates • Synthetic opioids – Codeine – Fentanyl – Morphine – Methadone • Semi-synthetic opioids – Meperidine – Oxymorphone – Tramadol – Oxycodone – Propoxyphene – Hydromorphone – Levorphanol – Hydrocodone – Tapentadol – Buprenorphine • Anticonvulsant • Muscle
    [Show full text]
  • Dextrorphan Binds to Opioid Receptors in Guinea-Pig Brain Membranes And
    Proc. Natl. Acad. Sci. USA Vol. 87, pp. 1629-1632, March 1990 Pharmacology Dextrorphan binds to opioid receptors in guinea-pig brain membranes and is an antagonist at opioid receptors in myenteric plexus (binding/guinea-pig ileum/levorphanol/stereoselectivity) AVRAM GOLDSTEIN AND ASHA NAIDU Department of Pharmacology, Stanford University, Stanford, CA 94305 Contributed by Avram Goldstein, December 11, 1989 ABSTRACT Dextrorphan (+)-tartrate, purified by re- LaRoche); [D-Ala,MePhe4,Gly-ol5]enkephalin (DAGO; Pe- peated crystallization to remove all traces of the enantiomer ninsula Laboratories) (2); trans-3,4-dichloro-N-methyl- levorphanol, binds to IL, 6, and K sites on guinea-pig brain N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide methane- membranes with lower affinities (by a factor of400-3200) than sulfonate (U50,488; Upjohn) (3); (-)-naloxone hydrochloride levorphanol. In the guinea-pig ileum myenteric plexus longi- (NAL; Endo Laboratories, New York); normorphine hydro- tudinal muscle preparation (GPI), dextrorphan, at 100-200 chloride (NOR) and (+)-naloxone hydrochloride (National ,uM, inhibits the electrically stimulated twitch, but this action Institute on Drug Abuse); N-methyl-D-aspartic acid (NMDA), is not blocked or reversed by naloxone; both (+)- and (-)- aminophosphonovalerate, norepinephrine (levarterenol), at- naloxone produce similar non-opioid twitch inhibition at com- ropine, and eserine (physostigmine) (Sigma). parable concentrations. At 10-20 jaM, dextrorphan' blocks and Preparation ofDEXp. [3H]LEV (Ro 1-5431/701, Hoffmann- reverses the twitch inhibition due to ,u and KWagonists, but the LaRoche; 17.4 Ci/mmol; 1 Ci = 37 GBq) was purified' by blockade can be overcome only partially by increasing the preparative reversed-phase HPLC (Waters, C18 AgBondaPak, agonist concentration.
    [Show full text]
  • Neurolept Anaesthesia: a Comparison with a Conventional Technique for Major Surgery*
    NEUROLEPT ANAESTHESIA: A COMPARISON WITH A CONVENTIONAL TECHNIQUE FOR MAJOR SURGERY* S. A. McDOWELL,M.B., F./~.A.I~.C.S. AND J. W. DUNDEE, 1VI.D.,PH.D., F.F.A.H.C.S. IN THE PAST DECADE, the term "neuroleptic" has been increasingly used to describe the effects of certain drugs on the central nervous system. It is usually used to signify the production of tranquillity and mental detachment, without a marked soporific effect. If a narcotic analgesic is used in combination with a neuroleptic drug, then a state of neurolept-analgesia is produced and if, in this state, a hypnotic is added to produce sleep, the result is neurolept anaesthesia (NLA). Since the introduction of this form of anaesthesia by De Castro and Mundeleer 1 a great variety of techniques of NLA have been described and many claims made for its advantages over more conventional forms of anaesthesia. 2-6 Among these are: (a) stability of the cardiovascular system, making it particularly suited for the poor-risk patient. (b) profound analgesia, which extends into the postoperative period and results in comfort for the patient and ease of management. (e) little postoperative nausea and vomiting. (d) rapid recovery of consciousness with good tolerance of endotraeheal tubes and patient cooperation. In spite of these advantages, neuroleptanaesthesia has not found acceptance with all workers 7 and recently, the usefulness of the drugs used in NLA has been ques- tioned by workers from this department, s,9 The neuroleptic drug commonly used in this form of anaesthesia is droperidol and it is usually given in conjunction with the analgesic fentanyl.
    [Show full text]
  • Levorphanol Use: Past, Present and Future
    Postgraduate Medicine ISSN: 0032-5481 (Print) 1941-9260 (Online) Journal homepage: http://www.tandfonline.com/loi/ipgm20 Levorphanol Use: Past, Present and Future Jeffrey Gudin, Jeffrey Fudin & Srinivas Nalamachu To cite this article: Jeffrey Gudin, Jeffrey Fudin & Srinivas Nalamachu (2015): Levorphanol Use: Past, Present and Future, Postgraduate Medicine, DOI: 10.1080/00325481.2016.1128308 To link to this article: http://dx.doi.org/10.1080/00325481.2016.1128308 Accepted author version posted online: 03 Dec 2015. Submit your article to this journal View related articles View Crossmark data Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ipgm20 Download by: [Jeffrey Fudin] Date: 03 December 2015, At: 20:32 Publisher: Taylor & Francis Journal: Postgraduate Medicine DOI: 10.1080/00325481.2016.1128308 Levorphanol Use: Past, Present and Future Authors: Jeffrey Gudin1, Jeffrey Fudin2, and Srinivas Nalamachu3 Affiliations: 1Director, Pain Management and Palliative Care, Englewood Hospital and Medical Center, Englewood, NJ, and Clinical Instructor, Anesthesiology, Icahn School of Medicine at Mount Sinai, New York, NY. 2Adjunct Associate Professor, Albany College of Pharmacy and Health Sciences and also Western New England University College of Pharmacy Director, PGY2 Pain Residency and Clinical Pharmacy, Specialist, Pain Management Stratton VA Medical Center, Albany, NY 3President and Medical Director, International Clinical Research Institute, Overland Park, KS, and Adjunct Associate Professor, Temple University School of Medicine, Downloaded by [Jeffrey Fudin] at 20:32 03 December 2015 Philadelphia, PA. Running Title: Levorphanol Use: Past, Present and Future Corresponding Author Srinivas Nalamachu Srinivas R. Nalamachu MD International Clinical Research Institute, Inc.
    [Show full text]
  • Chronic Pain Levorphanol Methadone and the N Methyl D Aspartate
    JPM-2009-0105-Letter to the Editor_1P.3d 07/21/09 2:53pm Page 1 JPM-2009-0105-Letter to the Editor_1P JOURNAL OF PALLIATIVE MEDICINE Volume 12, Number 9, 2009 Letter to the Editor ª Mary Ann Liebert, Inc. DOI: 10.1089=jpm.2009.0105 Chronic Pain: Levorphanol, Methadone, and the N-Methyl-d-Aspartate Receptor Dear Editor: patients, whose pain score was reduced to a score of 4 to 5. The Not every clinician is in a position to undertake controlled overall response rate to treatment with methadone ap- trials to advance the science and practice of medicine. Even proached 75%. The pain relief provided by levorphanol was researchers in academic institutions are subject to problems quite similar to that from methadone. Of the 73 patients who with funding the cost of studies. End-of-life care, which is received levorphanol, 35 had an excellent response and 14 increasingly provided in the home, is beset with ethical and experienced fair relief. The overall response rate to levor- logistical problems regarding the use of evidence-based prin- phanol was 70%. ciples to study patients. Physicians practicing in home hos- Levorphanol is a m- and k-receptor agonist and an NMDA pice settings are in a much different environment than those receptor antagonist. With respect to effectiveness and adverse- who work in hospitals and teaching institutions, and studies effect profile, it is much like hydromorphone but offers these in those locations may not be comparable. important advantages: Levorphanol relieves neuropathic If a concept, new or old, is attractive to a physician because pain, and 1 dose is effective for 6, 8, or 12 hours as opposed to it may improve the care of patients and if a controlled trial is the 3 to 4 hours of relief afforded by hydromorphone.
    [Show full text]
  • Laws 2021, LB236, § 4
    LB236 LB236 2021 2021 LEGISLATIVE BILL 236 Approved by the Governor May 26, 2021 Introduced by Brewer, 43; Clements, 2; Erdman, 47; Slama, 1; Lindstrom, 18; Murman, 38; Halloran, 33; Hansen, B., 16; McDonnell, 5; Briese, 41; Lowe, 37; Groene, 42; Sanders, 45; Bostelman, 23; Albrecht, 17; Dorn, 30; Linehan, 39; Friesen, 34; Aguilar, 35; Gragert, 40; Kolterman, 24; Williams, 36; Brandt, 32. A BILL FOR AN ACT relating to law; to amend sections 28-1202 and 69-2436, Reissue Revised Statutes of Nebraska, and sections 28-401 and 28-405, Revised Statutes Cumulative Supplement, 2020; to redefine terms, change drug schedules, and adopt federal drug provisions under the Uniform Controlled Substances Act; to provide an exception to the offense of carrying a concealed weapon as prescribed; to define a term; to change provisions relating to renewal of a permit to carry a concealed handgun; to provide a duty for the Nebraska State Patrol; to eliminate an obsolete provision; to harmonize provisions; and to repeal the original sections. Be it enacted by the people of the State of Nebraska, Section 1. Section 28-401, Revised Statutes Cumulative Supplement, 2020, is amended to read: 28-401 As used in the Uniform Controlled Substances Act, unless the context otherwise requires: (1) Administer means to directly apply a controlled substance by injection, inhalation, ingestion, or any other means to the body of a patient or research subject; (2) Agent means an authorized person who acts on behalf of or at the direction of another person but does not include a common or contract carrier, public warehouse keeper, or employee of a carrier or warehouse keeper; (3) Administration means the Drug Enforcement Administration of the United States Department of Justice; (4) Controlled substance means a drug, biological, substance, or immediate precursor in Schedules I through V of section 28-405.
    [Show full text]
  • Levorphanol: the Forgotten Opioid
    Support Care Cancer (2007) 15: 259–264 DOI 10.1007/s00520-006-0146-2 REVIEW ARTICLE Eric Prommer Levorphanol: the forgotten opioid Abstract Background: Levorphanol Similar to morphine, levorphanol Received: 8 June 2006 Accepted: 17 August 2006 (levo-3-hydroxy-N-methylmorphinan) undergoes glucuronidation in the liver, Published online: 13 October 2006 is a strong opioid that is the only and the glucuronidated products are # Springer-Verlag 2006 available opioid agonist of the excreted in the kidney. Levorphanol morphinan series. Levorphanol was can be given orally, intravenously, and originally synthesized as a pharmaco- subcutaneously. Objective: This logical alternative to morphine more article reviews the pharmacodynamics, than 40 years ago. It is considered a pharmacology, and clinical efficacy step-3 opioid by the World Health for this often overlooked step-3 opioid. Organization (WHO) and has a greater Conclusion: The long half-life of potency than morphine. Analgesia the drug increases the potential for E. Prommer (*) VIP Palliative Care Program, produced by levorphanol is mediated drug accumulation. Levorphanol Greater Los Angeles Healthcare, via its interactions with μ, δ,andκ has clinical efficacy in neuropathic Division of Hematology/Oncology, opioid receptors. Levorphanol is also pain. UCLA School of Medicine, an N-methyl-D-aspartate (NMDA) 11301 Wilshire 111-H, receptor antagonist. There is evidence Los Angeles, CA, USA e-mail: [email protected] that levorphanol may inhibit uptake Keywords Pain . Levorphanol . Tel.: +1310-478-3711 of norepinephrine and serotonin. Opioids . NMDA . Glucuronidation Introduction and it is important that clinicians not forget that this is an option for moderate to strong pain.
    [Show full text]
  • Coash, 27; Dubas, 34; Friend, 10; Mcgill, 26; Pirsch, 4; Rogert, 16; Wallman, 30; Giese, 17
    LB 123 LB 123 LEGISLATIVE BILL 123 Approved by the Governor February 26, 2009 Introduced by Karpisek, 32; Christensen, 44; Coash, 27; Dubas, 34; Friend, 10; McGill, 26; Pirsch, 4; Rogert, 16; Wallman, 30; Giese, 17. FOR AN ACT relating to the Uniform Controlled Substances Act; to amend section 28-405, Reissue Revised Statutes of Nebraska; to regulate Salvia divinorum or Salvinorin A; and to repeal the original section. Be it enacted by the people of the State of Nebraska, Section 1. Section 28-405, Reissue Revised Statutes of Nebraska, is amended to read: 28-405 The following are the schedules of controlled substances referred to in the Uniform Controlled Substances Act: Schedule I (a) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation: (1) Acetylmethadol; (2) Allylprodine; (3) Alphacetylmethadol, except levo-alphacetylmethadol which is also known as levo-alpha-acetylmethadol, levomethadyl acetate, and LAAM; (4) Alphameprodine; (5) Alphamethadol; (6) Benzethidine; (7) Betacetylmethadol; (8) Betameprodine; (9) Betamethadol; (10) Betaprodine; (11) Clonitazene; (12) Dextromoramide; (13) Difenoxin; (14) Diampromide; (15) Diethylthiambutene; (16) Dimenoxadol; (17) Dimepheptanol; (18) Dimethylthiambutene; (19) Dioxaphetyl butyrate; (20) Dipipanone; (21) Ethylmethylthiambutene; (22) Etonitazene; (23) Etoxeridine; (24) Furethidine;
    [Show full text]
  • Separation, Quantification and Control of Enatiomers of the Key Starting Material of Dextromethorphan Hydrobromide
    Journal of Applied Pharmaceutical Science Vol. 8(08), pp 032-038, August, 2018 Available online at http://www.japsonline.com DOI: 10.7324/JAPS.2018.8805 ISSN 2231-3354 Separation, Quantification and Control of Enatiomers of the Key Starting Material of Dextromethorphan Hydrobromide Ajit Anerao*, Vishal Solase, Amol More, Nitin Pradhan R&D Centre (API), Wanbury Ltd., EL-16, TTC Industrial Estate, Mahape, Navi Mumbai 400710, India. ARTICLE INFO ABSTRACT Article history: Objective: Enantiomeric resolution of racemic 1-(4-Methoxybenzyl)-1,2,3,4,5,6,7,8-octahydroisoquinoline, a key Received on: 16/05/2018 starting material in the synthesis of the antitussive agent dextromethorphan hydrobromide. Material and method: Accepted on: 11/07/2018 Chiral liquid chromatographic method is developed and enantiomers are resolved on a Chiralpak ID-3 column using Available online: 31/08/2018 gradient mode of elution. Mobile phase A and B containing a mixture of 0.1% diethylamine in acetonitrile and 0.1% diethylamine in methanol respectively are optimized with the timed programme. The flow rate is 1.0 mL/minute and the column temperature was maintained at 40°C. Ultraviolet detection was performed at 280 nm wavelength and Key words: the injection volume was 20 μL. Results: The resolution between the enantiomers is found to be more than 2.5. The HPLC; chiral purity; developed method is extensively validated and proved to be robust. The limit of detection and limit of quantification dextromethorphan; of unwanted (R)-enantiomer is found to be 0.0075% and 0.025% with respect to test concentration, respectively. The development; validation.
    [Show full text]